

# Overview of Chikungunya Virus Infection, Pathogenesis and Clinical Outcome

ศาสตราจารย์(เกียรติคุณ) ดร.ศุขธิดา อูบล  
มหาวิทยาลัยมหิดล


# Cumulative impact during the last decade

**CHIKV-rheumatic disease in > 110 countries**


**An estimated annual loss of over 106,000 DALYs (disability-adjusted life years)**

**Reported total direct costs associated with Chikungunya  
Fever ranged from US\$ 3.5 million (US Virgin Islands,  
2014-2015) to US\$ 83.6 billion (Region of the Americas,  
2013-2015)**

Will it become a global health problem?





Italy (2007) 200 cases, (2017) >400 cases, (2025) 1<sup>st</sup> autochthonous cases (local transmission)



France (2010, 2014) ; 2025(799 imported cases; 30 autochthonous cases) 12 clusters of CHIKV transmission



# Recent epidemic in China




Timeline of the 2025 chikungunya outbreak in China.

*International Journal of Infectious Diseases* (2025),  
doi:<https://doi.org/10.1016/j.ijid.2025.108089>

*Journal of Infection*, (2025)  
doi:<https://doi.org/10.1016/j.jinf.2025.106591>











ECSA lineage, Asian lineage, Indian Ocean Lineage



a




# Replication cycle






Replication of the viral RNA genome occurs in specialized membranous replication organelles (ROs) or spherules, which contain the viral replication complex.



Laurent et al. eLife 2022;11:e83042.






# Chikungunya virus cell-to-cell transmission is mediated by intercellular extensions in vitro and in vivo

Nat Microbiol. 2023 September ; 8(9): 1653–1667.  
doi:10.1038/s41564-023-01449-0.

Mock

WT-CHIKV

CHIKV



CHIKV cell-to-cell transmission exploits the target cell endocytic pathway including dynamin-dependent uptake, Rab5-mediated delivery to early endosomes, and exposure to endosomal low pH.


# CHIKV infection and PATHOGENESIS

FEVER (>90%)


Myalgia(>90%)

Polyarthralgia(95->95%)


Rash (40-50%)



# Timeline of CHIKV pathogenesis







# Acute CHIKD

## Polyarthralgia


## Myalgia

Myoblast, skeleton muscle





CHIKV

IP-10, MIP-1a, IL-8



IL-1 $\beta$ , IL-5, IL-6, IL-7, IL-8, IL-10,  
IL-12, IL-15, IL-17A, IL-27, IL-29,  
IFN- $\alpha$ , UL-18, IL-6, G-CSF, GM-CSF,  
CCL2, C5a, IP-10, TNF- $\alpha$ , IFN- $\gamma$ ,  
MMP-1, MMP-3





# Chronic Chick Disease

**Synovial fluid : dsRNA but not viral RNA**

## Severe and prolong inflammation :

IL-1b, IL-6, IL-8, MCP-1/CCl2, MMp-1, MMp3, GMCSF, IL-17A, IL-27 and IL-29

## Damage of connective tissues :

bone erosion, periostitis, enthesopathies






# Chronic chikungunya disease

## 3 major mechanisms of connective tissue damage


1. CHIKV directly infects synovial fibroblast, chondrocytes, myocytes leading to inflammation and damage.
2. CHIKV infection is found to alter the RANKL/OPG ratio resulting in bone loss.
3. CHIKV infection results in a loss of proteoglycans in the cartilage matrix, resulting in bone loss.

# Bone damage in chronic CHIKD



Levels of dsRNA in serum and synovial fluid correlates with bone erosion.  
dsRNA induced PAMP activation in joints, thus, causes persistent inflammation.

## RANKL-dependent mechanism



## OPG (osteoprotegerin)

RANKL-induced osteoclast

Bone formation

# Determinants for disease severity


## Viral factor

### Virus strain and mutation : effect on transmission and immune evasion

1. Mutations in nonstructural genes:



nsP1(R532H)  
nsP2(E515V) } Increased type 1 interferon production

E1 (A226V) → Increase transmission by *A. albopictus*





# Heterogeneity of clinical isolates



Plaque purification and in vitro model

Large plaque CHIKVs

Small plaque CHIKVs

> IL-6, IL8, MCP-1

> Promoting monocyte/macrophage migration

Reverse genetics

Cloned-large plaque CHIKV

Cloned-small plaque CHIKV

Small-plaque CHIKV caused more severe disease in mouse model

# Determinants for disease severity (continue)

## Human genetics

HLA-DRB1X04-HLA-DQB1X03 haplotype → Susceptible to CHIKV infection  
HLA-DRB1X11, HLA-DQB1X03 haplotype → Resistance to CHIKV infection

## Co-infection

1. Daniela Polania, et al. : Columbia, CHIKV epidemic 2015 (PLOS Neglc Trop Dis. 2025)

Caron, MI. study in South Africa,

No evidence that co-infection between DENV and CHIKV were associated with a worse clinical outcomes.

2. Gandhi, et. al. (Int. J. Health. Biomed. Res. 2015)

Mortality rate in co-infection = 12%

Mortality rate in mono-infection = 2%

# Diagnosis


## 1. RT-PCR ( China CDC Weekly, Vol7, N0. 33)

Blood = 90%

Saliva = 68%

Throat swabs =15%

Urine = 11%





# Diagnosis

## 2. Antibody detection

**TABLE 2 |** Commercially available Chikungunya Virus (CHIKV) diagnostic assays in South Asia with principle of functions (Gaibani et al., 2016; Centers for Disease Control and Prevention (CDC), 2021; World Health and Organization (WHO), 2021).

Manufacturer	Country of origin	Principle	IgM	IgG
Abcam	Germany	IgM human ELISA kit	+	/
CTK Biotech	United States	CHIK IgM combo rapid test	+	/
CTK Biotech	United States	RecombiLISA CHIK IgM	+	
DRG*	Germany	CHIK IgM micro-capture ELISA	+	/
DRG	Germany	ELISA	/	+
Euroimmun	Germany	Anti-CHIKV IIFT	+	+
Euroimmun	Germany	Anti-CHIKV ELISA	+	+
GenWay	Germany	IgM-capture ELISA	+	/
GenWay	Germany	ELISA	/	+
IBL international	Germany	IgM micro-capture ELISA	+	/
IBL international	Germany	IgG-capture ELISA	/	+
InBios	United States	CHIKj-MAC-ELISA	+	+
Novatec	Germany	IgM-capture ELISA	+	/
Novatec	Germany	ELISA	/	+
SD Diagnostics	South Korea	CHIKa IgM ELISA	+	/
SD Diagnostics	South Korea	SD BIOLINE Chikungunya IgM	+	/

\*Only for research purposes.

# Prevention and treatment

## Treatment

There is no anti-CHIKV drug available at this moment.

**As of Friday, August 22, 2025, FDA suspended the US license for IXCHIQ.**

## Prevention

The first FDA (USA) approved vaccine is a live-attenuated vaccine, IxchIQ. 2023

CHIKV(LR2006-OPY), deletion in nsP3, 1 dose IM, >18-65 years, not recommended for pregnancy women.

One dose can stimulate > 98% seroconversion.

**Adverse effect** : CHIKV-like syndrome , may cause serious in fetus.

## Prevention (continue)

The only licensed vaccine available is **VIMKUNYA**.

**VIMKUNYA** is a VLP platform containing E1, E2, and C.

1 dose IM, >12 years,

1 dose can induced NT Ab in 98.7% of vaccinees.

**Adverse effect: no report**



Table 1. *Cont.*

Vaccine	Technology	Virus Strain	CHIKV Immunogen	Number of Doses	Development Stage	Developer	Reference
CHIKV TSI-GSD-218	Live attenuated	Southeast Asian strain/AF15561	Whole Virus	Single-dose	Phase II	US Army Medical Research Institute of Infectious Diseases and University of Maryland	[114,115]
VAL-181388	mRNA-based	-	mRNA encoding C, E3, E2, 6k, E1	Two doses	Phase I	ModernaTX, Inc	NCT03325075
CHIKV001 (ChAdOx1-Chik)	Adenoviral vector	Multiple	C, E3, E2, 6k, E1	Single-dose	Phase I	Jenner Institute, University of Oxford	[116]
mRNA-1944	mLNP-mRNA-based	-	mRNA encoding CHKV-24 IgG (monoclonal)	One or Two doses	Phase I	ModernaTX, Inc	[117]

Abbreviations: MV measles virus; VLP virus-like particle;  $\Delta$ 5nsP3 five viruses with deletions in the nsP3 protein region ( $\Delta$ 5nsP3 mutants); LNP lipid nanoparticle encapsulated.

Thank you for your attention.



ต้นไผ่แล้ว

